Abstract
Drug instillation via a topical route is preferred since it is desirable and convenient due to the noninvasive and easy drug access to different segments of the eye for the treatment of ocular ailments. The low dose, rapid onset of action, low or no toxicity to the local tissues, and constrained systemic outreach are more prevalent in this route. The majority of ophthalmic preparations in the market are available as conventional eye drops, which rendered <5% of a drug instilled in the eye. The poor drug availability in ocular tissue may be attributed to the physiological barriers associated with the cornea, conjunctiva, lachrymal drainage, tear turnover, blood–retinal barrier, enzymatic drug degradation, and reflex action, thus impeding deeper drug penetration in the ocular cavity, including the posterior segment. The static barriers in the eye are composed of the sclera, cornea, retina, and blood–retinal barrier, whereas the dynamic barriers, referred to as the conjunctival and choroidal blood flow, tear dilution, and lymphatic clearance, critically impact the bioavailability of drugs. To circumvent such barriers, the rational design of the ocular therapeutic system indeed required enriching the drug holding time and the deeper permeation of the drug, which overall improve the bioavailability of the drug in the ocular tissue. This review provides a brief insight into the structural components of the eye as well as the therapeutic challenges and current developments in the arena of the ocular therapeutic system, based on novel drug delivery systems such as nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, in situ gel, dendrimers, contact lenses, implants, and microneedles. These nanotechnology platforms generously evolved to overwhelm the troubles associated with the physiological barriers in the ocular route. The controlled-drug-formulation-based strategic approach has considerable potential to enrich drug concentration in a specific area of the eye.
Highlights
The eye is a unique, complex, and highly important part of the human body, which is related to various physiological and anatomical barriers
These findings suggest that nanosize micelle could evade the physiological barriers in the ocular region and efficiently deliver drug carriers to the posterior ocular tissues [33]
Drug delivery challenges due to the various ocular barriers confoundpotential setbacks for scientists working on targeted drug delivery in the ocular tissues
Summary
The eye is a unique, complex, and highly important part of the human body, which is related to various physiological and anatomical barriers. The speedy drainage of the drug from topical application reduces the pharmacological action of the drug, which needs to be compensated with increased dosing frequency as well as the part of the drug that has reached systemic circulation through the various routes that could cause a systemic toxic effect. To surmount these problems, novel ophthalmic preparations, viz., NPs, liposomes, prodrug, nanomicelles, nanosuspensions, dendrimers, contact lenses, implants, microneedles, and in situ gel, have promising results, which have been explicated in the last few decades to alleviate better drug solubility, dissolution, absorption, and bioavailability in a controlled, sustained, and prolonged period [1,3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
